MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer

Tan, Daniel; Farago, A.; Kummar, S.; Moreno, V.; Patel, Jay; Lassen, Ulrik V.; Solomon, Benjamin; Rosen, Lee S.; Leyvraz, S.; Reeves, John A.; Brega, Nicoletta; Dima, Laura; Childs, Barrett H.; Drilon, A.

doi:10.1016/j.jtho.2021.01.253

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For entrectinib, there were 10 patients with NSCLC with an ORR of 70% and a median PFS of 14.9 months, 81 whereas for larotrectinib, there were 14 patients with lung cancer with an ORR of 71% and a median PFS was not reached. 82 Despite the excellent durable outcomes, the challenge for NTRK rearrangements remains a diagnostic one, because of the sheer rarity of this alteration and the varying ability of different assays to detect NTRK1, NTRK2 , or NTRK3 rearrangements. Upfront sequencing, preferentially with an RNA-based assay, or screening with immunohistochemistry followed by confirmation of positivity with sequencing is the potential strategy for detection of NTRK rearrangements in unselected populations.…”

Section: Oncogenic Driver Alterationsmentioning

confidence: 99%

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Tan

2022

JCO

348

244

View full text Add to dashboard Cite

Lung cancer has traditionally been classified by histology. However, a greater understanding of disease biology and the identification of oncogenic driver alterations has dramatically altered the therapeutic landscape. Consequently, the new classification paradigm of non–small-cell lung cancer is further characterized by molecularly defined subsets actionable with targeted therapies and the treatment landscape is becoming increasingly complex. This review encompasses the current standards of care for targeted therapies in lung cancer with driver molecular alterations. Targeted therapies for EGFR exon 19 deletion and L858R mutations, and ALK and ROS1 rearrangements are well established. However, there is an expanding list of approved targeted therapies including for BRAF V600E, EGFR exon 20 insertion, and KRAS G12C mutations, MET exon 14 alterations, and NTRK and RET rearrangements. In addition, there are numerous other oncogenic drivers, such as HER2 exon 20 insertion mutations, for which there are emerging efficacy data for targeted therapies. The importance of diagnostic molecular testing, intracranial efficacy of novel therapies, the optimal sequencing of therapies, role for targeted therapies in early-stage disease, and future directions for precision oncology approaches to understand tumor evolution and therapeutic resistance are also discussed.

show abstract

Section: Oncogenic Driver Alterationsmentioning

confidence: 99%

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Tan

2022

JCO

348

244

View full text Add to dashboard Cite

show abstract

Difficulties on the access to innovative targeted therapies for lung cancer in Spain

Calvo,

Camps,

Carcereny

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

Purpose Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain. Methods Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments. Results More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System. Conclusion SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.

show abstract

MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer

Cited by 2 publications

References 0 publications

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Difficulties on the access to innovative targeted therapies for lung cancer in Spain

Contact Info

Product

Resources

About